Inspirna, Inc.
Small molecule and biologic therapeutics targeting metastasis drivers discovered through proprietary RNA-DRIVEr platform and microRNA mapping
- Sector
- Biotech
- Headquarters
- NEW YORK, NY
- Latest Form D
- $47.2M, Jul 2022
- Total capital
- $134M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $134M
- 5 Form D · last Jul 2022
- 52 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 10
- 16 pending · first 2021
- Rank in peer group#167 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 5th filing$47.2M
- Private capital raisedForm D · SEC · 4th filing$6M
- Private capital raisedForm D · SEC · 3rd filing$39.8M
- Private capital raisedForm D · SEC · 2nd filing$33M
- Private capital raisedForm D · SEC · 1st filing$8M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#167 · top 12%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Masoud TavazoieResearcherExecutive Officer, DirectorLinked by 1 patent
- Antoine PapiernikDirectorNamed in SEC Form D filings
- David DarstExecutive OfficerNamed in SEC Form D filings
- Dieter WeinandDirectorNamed in SEC Form D filings
- Eric RowinskyDirectorNamed in SEC Form D filings
- Jack NielsenDirectorNamed in SEC Form D filings
Show all 10 people
- Jue PuDirectorNamed in SEC Form D filings
- Michael GinderDirectorNamed in SEC Form D filings
- Peter Van VlasselaerDirectorNamed in SEC Form D filings
- Raymond CamahortDirectorNamed in SEC Form D filings
What it has protected
USPTO · 10 granted of 26- PendingApoe Genotyping In Cancer Prognostics And TreatmentUSPTOApplication 19062247
- PendingFormulations With Improved StabilityUSPTOApplication 18777110
- GrantedHigh-affinity Anti-mertk Antibodies And Uses ThereofUSPTOUS 12,281,174
Show all 26 patent records
- Apoe Genotyping In Cancer Prognostics And TreatmentAug 7, 2025 · Application 19062247Pending
- Formulations With Improved StabilityJun 12, 2025 · Application 18777110Pending
- High-affinity Anti-mertk Antibodies And Uses ThereofApr 22, 2025 · US 12,281,174Granted
- Metal Salts And Uses ThereofMar 25, 2025 · US 12,258,303Granted
- Anti-mertk Agonistic Antibodies And Uses ThereofDec 10, 2024 · US 12,162,942Granted
- Methods Of Treating CancerOct 24, 2024 · Application 18653106Pending
- Mertk Peptides And Uses ThereofAug 22, 2024 · Application 18559718Pending
- Methods Of Treating CancerJun 18, 2024 · US 12,011,427Granted
- Compositions And Methods For Inhibiting Creatine Transport As A Treatment For CancerJun 6, 2024 · Application 18417491Pending
- Metal Salts And Uses ThereofJan 23, 2024 · US 11,878,956Granted
- Formulations With Improved StabilityApr 18, 2023 · US 11,629,118Granted
- Anti-mertk Agonistic Antibodies And Uses ThereofMar 28, 2023 · US 11,613,588Granted
- Methods Of Treating CancerOct 20, 2022 · Application 17641904Pending
- Metal Salts And Uses ThereofOct 4, 2022 · US 11,459,292Granted
- Apoe Genotyping In Cancer Prognostics And TreatmentApr 28, 2022 · Application 17434359Pending
- Polymorphs And Uses ThereofJan 4, 2022 · US 11,214,536Granted
- Metal Salts And Uses ThereofNov 16, 2021 · US 11,174,220Granted
- Methods Of Treating CancerApplication PCTUS2020064317Pending
- Methods Of Treating CancerApplication PCTUS2020050075Pending
- Mertk Peptides And Uses ThereofApplication PCTUS2022029185Pending
- Formulations With Improved StabilityApplication 18529325Pending
- Compositions And Methods For Inhibiting Creatine Transport As A Treatment For CancerApplication PCTUS2022073884Pending
- Compositions And Methods For Inhibiting Creatine Transport As A Treatment For CancerApplication 63223926Pending
- Mertk Peptides And Uses ThereofApplication 63189036Pending
- Formulations With Improved StabilityApplication 18194936Pending
- Metal Salts And Uses ThereofApplication PCTUS2020064456Pending
Related companies, and why
- Lenz Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- COMPUTCHEM LLCSimilar federal contract value in Biotech · null in contracts
- Syndax PharmaceuticalsSimilar federal contract value in Biotech · null in contracts
- SATIETY INCSimilar federal contract value in Biotech · null in contracts
- Altesa BioSciences, Inc.Similar federal contract value in Biotech · null in contracts
- SOUVIE BIODELIVERY LLCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .